psa 1

This Prostate Specific Antigen 1 peptide was used in the immunotherapy of cancer experiments.

PSA1 141-150 acetate is used in the immunotherapy of cancer experiments that is a prostate specific antigen 1 peptide.

PSA-IN-1 (compound 19) is an inhibitor of puromycin-sensitive aminopeptidase (PSA) with an IC50 value of 7 nM, and it exhibits analgesic activity.

ROS inducer 1 is a small molecule compound with bactericidal activity that inhibits the production of ROS in Xanthomonas axonopodis pv. citri (Xac), Xanthomonas oryzae pv. oryzae (Xoo) and Pseudomonas syringae pv. actinidiae (Psa). ROS inducer 1 induces ROS production in Xanthomonas cells and can be used to study bacterial infections in crops.

XYD049 (compound 7d) is a CRBN-type molecular glue targeting GSPT1, with a DC50 of 19 nM, used for researching MYC-driven castration-resistant prostate cancer (CRPC). It effectively inhibits the growth of 22Rv1 cells (IC50 = 7 nM) and exhibits antitumor efficacy in vivo. XYD049 downregulates CRPC-associated oncogenes in 22Rv1 cells, including AR, AR-v7, PSA, and c-Myc. XYD049 comprises a molecular glue linker (black part) NH2-C5-NH-Boc, a CRBN-type E3 ligase ligand (blue part) Thalidomide 4-fluoride, and a target protein ligand (red part) GSPT1 ligand-1, with the E3 ligase ligand + linker forming the conjugate E3 Ligase Ligand-linker Conjugate 158.

AIM-100 is a Ack1 inhibitor (IC50: 24 nM).

Asperglaucin A, an atypical phthalide-like derivative, exhibits potent antibacterial activities, demonstrating effectiveness against the plant pathogens Pseudomonas syringae pv actinidae (Psa) and Bacillus cereus, with a minimum inhibitory concentration (MIC) of 6.25 μM [1].

Asperglaucin B, an alkylated salicylaldehyde derivative isolated from the fungus Aspergillus chevalieri SQ-8, exhibits significant antibacterial properties. This compound demonstrates potent activity against the plant pathogens Pseudomonas syringae pv actinidae (Psa) and Bacillus cereus, achieving a minimum inhibitory concentration (MIC) value of 6.25 μM [1].

Clazakizumab represents a highly specialized humanized monoclonal antibody specifically engineered to target the human cytokine interleukin-6 with exceptional binding affinity and selectivity, effectively facilitating the measurable neutralization of ligand-mediated signaling across various preclinical experimental models to evaluate the suppression of systemic inflammatory responses and the inhibition of the JAK/STAT cascade during strictly monitored laboratory observation periods and functional protein-protein interaction assays.

Topsalysin, a prostate-specific antigen (PSA)-activated protoxin, comprises a synthetic proaerolysin fusion protein targeting human prostate-specific antigen. This compound has demonstrated tumor-suppressive effects in a mouse model [1].